Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Income from Continuing Operations: 2012-2024

Historic Income from Continuing Operations for Sunshine Biopharma (SBFM) over the last 11 years, with Dec 2024 value amounting to -$5.1 million.

  • Sunshine Biopharma's Income from Continuing Operations rose 26.21% to -$883,820 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 41.81%. This contributed to the annual value of -$5.1 million for FY2024, which is 13.94% down from last year.
  • Per Sunshine Biopharma's latest filing, its Income from Continuing Operations stood at -$5.1 million for FY2024, which was down 13.94% from -$4.5 million recorded in FY2023.
  • In the past 5 years, Sunshine Biopharma's Income from Continuing Operations registered a high of -$2.8 million during FY2020, and its lowest value of -$26.7 million during FY2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$5.1 million (2024), whereas its average is -$12.1 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 346.70% in 2021, then spiked by 83.15% in 2023.
  • Yearly analysis of 5 years shows Sunshine Biopharma's Income from Continuing Operations stood at -$2.8 million in 2020, then plummeted by 346.70% to -$12.4 million in 2021, then plummeted by 115.05% to -$26.7 million in 2022, then soared by 83.15% to -$4.5 million in 2023, then declined by 13.94% to -$5.1 million in 2024.